Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
The company will provide free Diagnostics Service- X-ray Tele Radiology Services in District Hospitals / Sub-district Hospitals / Community Health Centers in the State of Tripura.
Based on a post hoc analysis, fewer required respiratory interventions
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
